Loading…
Chinese life-science reagent supplier making recombinant proteins and antibodies for biopharma R&D, diagnostics and vaccine development.
Chinese life-science reagent supplier making recombinant proteins and antibodies for biopharma R&D, diagnostics and vaccine development.
Sells research-grade proteins and antibodies from a catalogue in small lots to labs, and also does contract research and manufacturing work for drug developers. Product sales carry the company, and a large share goes to customers abroad. Demand rose sharply with vaccine and diagnostic research during COVID.
In one line: A Chinese Bio-Techne/R&D Systems.
Moat: narrow (scale, process know-how, installed base). Broad, validated catalog of research-grade proteins used across many biopharma R&D pipelines.
Headquarters: Beijing, China · Founded: 2009 · Employees: 1,069
Size Sino Biological (301047.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.98B, the 1281st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥106.59 on 6 Nov 2026.
Performance Over six months the shares gained 50.0%, against -10.0% for the median peer and -16.4% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 20.0% over the last twelve months (peer median +9.4%); the operating margin is 16.8% (peer median 12.8%).
Valuation It trades at 63.8× forward earnings against a peer median of 21.4× (2nd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is -15%, so the hurdle is +52 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.1 points below its cost of capital (11.0% WACC).
Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥792M | CN¥694M | CN¥614M | CN¥646M | CN¥568M |
| Revenue growth | — | +13% | -5% | +14% | — |
| Gross profit | CN¥618M | CN¥448M | CN¥389M | CN¥481M | CN¥455M |
| EBITDA | n/a | CN¥191M | CN¥130M | CN¥213M | CN¥247M |
| Net income | CN¥179M | CN¥148M | CN¥122M | CN¥260M | CN¥303M |
| Free cash flow | CN¥120M | CN¥122M | CN¥130M | -CN¥645M | CN¥205M |
| Capital expenditure | CN¥159M | CN¥101M | CN¥69.9M | CN¥1.04B | CN¥156M |
| Total debt | CN¥41.1M | CN¥53.5M | CN¥67.4M | CN¥85.1M | CN¥70.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sino Biological 301047.SZ | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% |
| Acrobiosystems 301080.SZ | $2.72B | +95% | +29% | 17% | 64.9× | 45.0% |
| Bio-Techne TECH | $11.4B | +51% | 0% | 22% | 35.9× | 31.3% |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301047.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.9% | 0.0% | lowest of 21 |
| 6-month return | +50.0% | -10.0% | 2nd highest of 21 |
| Distance from 52-week high | -35.4% | -28.8% | 8th lowest of 21 |
| Revenue growth (TTM) | +20.0% | +9.4% | 4th highest of 21 |
| Operating margin | 16.8% | 12.8% | 10th highest of 21 |
| Forward P/E | 63.8× | 21.4× | 2nd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 36.8% | 9.1% | 2nd most demanding of 18 |
| Growth delivered (Del g) | -15.1% | +9.2% | lowest of 18 |
| Hurdle (Req g minus delivered) | +51.9 pp | -0.2 pp | most demanding of 18 |
| ROIC minus cost of capital | -4.1 pp | -0.4 pp | 6th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.89B | -18% | -1% | 8% | 8.3× | 0.4% | -0.2% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |